Clinical Trials Logo

Filter by:
NCT ID: NCT04462341 Terminated - Clinical trials for Peri-implant Mucositis

Efficacy of an Oral Hygiene Implant Protocol

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This study is designed to evaluate the effectiveness of cleaning around implants that hold a full denture in the mouth. Different oral hygiene protocols will be compared. Areas to measure are gum tissue color and consistency, bleeding and cleanliness. A questionnaire will be provided at the end of the study. This is a proof of concept study.

NCT ID: NCT04461600 Terminated - Clinical trials for Triple Negative Breast Cancer

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

TENACITY
Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.

NCT ID: NCT04460495 Terminated - Clinical trials for Malignant Brain Neoplasm

Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI

Start date: July 7, 2020
Phase: N/A
Study type: Interventional

This trial looks to study the safety and feasibility of using oxygen-enhanced molecular MRI to understand how cancer cells use oxygen differently than normal cells. Cancer cells tend to utilize (or not utilize) oxygen differently than normal cells. By using the oxygen-enhanced molecular MRI, researchers will be able to create spatial "maps" depicting areas of abnormal oxygen utilization unique to cancer. This type of information may be useful for diagnosing new cancers, understanding various "subtypes" of cancer that might utilize oxygen differently, or this information may be useful for evaluating new drugs that impact cancer metabolism.

NCT ID: NCT04459299 Terminated - Clinical trials for STEMI - ST Elevation Myocardial Infarction

CorPath GRX STEMI Study

TREAT GRX
Start date: September 28, 2020
Phase:
Study type: Observational

This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).

NCT ID: NCT04458948 Terminated - COVID-19 Clinical Trials

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

Start date: March 24, 2020
Phase: Phase 2
Study type: Interventional

This research is designed as an open-label,non-comparative prospective trial.

NCT ID: NCT04458909 Terminated - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Start date: December 9, 2020
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with the usual chemotherapy may work better than the standard chemotherapy alone in treating patients with nasopharyngeal cancer.

NCT ID: NCT04458298 Terminated - COVID-19 Clinical Trials

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

PRANA
Start date: August 11, 2020
Phase: Phase 2
Study type: Interventional

The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe COVID-19. The secondary purpose of Stage 1 and Stage 2 of this study is to determine the effect of OP-101 reducing proinflammatory cytokines biomarkers in severe COVID-19 Patients. A further secondary objective of Stage 2 of this study is: To evaluate the safety and tolerability of OP-101 in patients with severe COVID-19.

NCT ID: NCT04457817 Terminated - COVID Clinical Trials

Compensatory Reserve Index (CRI) for Management of COVID-19

Start date: December 1, 2020
Phase:
Study type: Observational

The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.

NCT ID: NCT04457336 Terminated - Clinical trials for Congenital Adrenal Hyperplasia

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Start date: August 26, 2020
Phase: Phase 2
Study type: Interventional

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg Tildacerfont QD.

NCT ID: NCT04457245 Terminated - Clinical trials for Stage III Prostate Cancer AJCC v8

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

PSMA-dRT
Start date: August 14, 2020
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared to dRT without PSMA PET (standard dRT).